Todeschini 2002.

Methods	Study design: cross‐over RCT Study time frame: not stated Duration of follow‐up: 3 dialysis sessions
Participants	Country: Italy Setting: single centre Stable patients on HD 3 times/week; HCT > 30%; informed consent Number: 9 Age: Mean 63.6 ± 7.2 years Sex (M/F): 3/6 Exclusion criteria: uncontrolled hypertension (diastolic BP > 100 mm Hg); clinical evidence of unstable angina pectoris; on drugs known to affect haemostasis; evidence of acute illness or neoplasia
Interventions	Treatment group AFB with a biocompatible high‐flux polyacrylonitrile (AN69) membrane for 3 sessions QB: 300 mL/min QD: 500 mL/min Duration of each dialysis session: 240 min Control group Bicarbonate HD with a biocompatible high‐flux polyacrylonitrile membrane (AN69) membrane QB: 300 mL/min QD: 500 mL/min Duration of each dialysis session: 240 min Co‐interventions: not stated
Outcomes	Kt/V Pre‐ and post‐dialysis systolic BP Difference between pre‐ and post‐dialysis systolic BP Pre‐ and post‐dialysis diastolic BP Difference between pre‐ and post‐dialysis diastolic BP
Notes	Exclusions post randomisation but pre‐intervention: not stated Stop or end point/s: not stated Additional data requested from authors: method of randomisation; details regarding blinding Funding: none stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not stated
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not stated
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear; no loss to follow‐up
Selective reporting (reporting bias)	High risk	Data for end of first phase of treatment not available
Other bias	High risk	Carry over effect present because of the cross‐over design; data not extractable for meta‐analysis